The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
AbstractLung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer. View Full-Text
Share & Cite This Article
Visconti, R.; Morra, F.; Guggino, G.; Celetti, A. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. Int. J. Mol. Sci. 2017, 18, 1374.
Visconti R, Morra F, Guggino G, Celetti A. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. International Journal of Molecular Sciences. 2017; 18(7):1374.Chicago/Turabian Style
Visconti, Roberta; Morra, Francesco; Guggino, Gianluca; Celetti, Angela. 2017. "The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy." Int. J. Mol. Sci. 18, no. 7: 1374.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.